At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants (OT2SUITE)
In Brief
A clinical study evaluating Oxytocin and Control for Prader-Willi Syndrome. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The objective of this study is to collect data on tolerance and effects of early treatment with oxytocin in children with Prader Willi Syndrome aged from 3 to 4 years and to compare these infants with not treated age-matched infants with Prader Willi Syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrader-Willi Syndrome
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedMar 2017
Primary CompletionMay 2018
Study CompletionDec 2018
TodayJul 2026
First PostedMar 16, 2017
Enrollment StartJan 1, 2017
Primary CompletionMay 1, 2018
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.3 years ago
Interventions
Oxytocindrug
Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
Controlother
Not treated.